Director/PDMR Shareholding

May 5, 2017

Advanced Medical Solutions Group plc
(“AMS” or the “Group”)

HomeRNS NewsDirector ShareholdingDirector/PDMR Shareholding
RNS Number : 3937E
Advanced Medical Solutions Grp PLC
05 May 2017
 

 

5 May 2017

            Advanced Medical Solutions Group plc

(“AMS”, the “Company” or the “Group”)

 

            Director/PDMR and PCA Shareholding

 

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), a leading developer and manufacturer of advanced products for the global surgical and advanced wound care markets, announces that the Trust which manages the Deferred Share Bonus Plan (“Plan”) on behalf of the employees of AMS has purchased ordinary shares of 5 pence each (“Ordinary Shares”) on 2 May 2017, at a price of 264.07p on behalf of Chris Meredith, Mary Tavener, Simon Coates, Rose Guang, Eddie Johnson, Becky Walmsley and Jeff Willis (“PDMRs”) as part of the Deferred Share Bonus Plan and, under the terms of the Plan, these shares will be held in trust on their behalf.

 

Following these transactions the beneficial ownership of the PDMRs is as follows:

 

Director/PDMR

Date purchased

Shares purchased

Resultant holding

Chris Meredith

Chief Executive Officer

2 May 2017

2,186

1,192,508

Mary Tavener

Chief Financial Officer

2 May 2017

1,684

1,829,813

Simon Coates

PDMR

2 May 2017

4,382

79,481

Rose Guang

PDMR

2 May 2017

7,224

36,059

Eddie Johnson

PDMR

2 May 2017

7,157

52,195

Becky Walmsley

PDMR

2 May 2017

2,381

3,469

Jeff Willis

PDMR

2 May 2017

5,226

130,085

 

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

 

1.

a)

Name: Chris Meredith

2.

a)

Position/status: Director/PDMR

b)

Initial notification/Amendment: Initial Notification

3.

a)

Name:   Advanced Medical Solutions Group plc

b)

LEI: 213800HJP6OWOSZI1L74

4.

a)

Description of the financial instrument, type of instrument: Ordinary Shares of 5p

Identification code: GB0004536594

b)

Nature of the transactions:

·        Purchase of 2,186 Ordinary Shares as part of the Deferred Share Bonus Plan on 2 May 2017

c)

Price(s) and volume(s):

Sale of shares:

Price(s)

Volume(s)

n/a

n/a

d)

Aggregated information: (Relates to those shares sold only)

Aggregated volume: n/a

Aggregated price: n/a

e)

Date of the transaction: 02/05/2017

f)

Place of the transaction: London Stock Exchange, AIM Market (XLON)

 

 

 

 

1.

a)

Name: Mary Tavener

2.

a)

Position/status: Director/PDMR

b)

Initial notification/Amendment: Initial Notification

3.

a)

Name:   Advanced Medical Solutions Group plc

b)

LEI: 213800HJP6OWOSZI1L74

4.

a)

Description of the financial instrument, type of instrument: Ordinary Shares of 5p

Identification code: GB0004536594

b)

Nature of the transactions:

·        Purchase of 1,684 Ordinary Shares as part of the Deferred Share Bonus Plan on 2 May 2017

c)

Price(s) and volume(s):

Sale of shares:

Price(s)

Volume(s)

n/a

n/a

d)

Aggregated information: (Relates to those shares sold only)

Aggregated volume: n/a

Aggregated price: n/a

e)

Date of the transaction: 02/05/2017

f)

Place of the transaction: London Stock Exchange, AIM Market (XLON)

 

 

 

 

 

 

 

1.

a)

Name: Simon Coates

2.

a)

Position/status: Director/PDMR

b)

Initial notification/Amendment: Initial Notification

3.

a)

Name:   Advanced Medical Solutions Group plc

b)

LEI: 213800HJP6OWOSZI1L74

4.

a)

Description of the financial instrument, type of instrument: Ordinary Shares of 5p

Identification code: GB0004536594

b)

Nature of the transactions:

·        Purchase of 4,382 Ordinary Shares as part of the Deferred Share Bonus Plan on 2 May 2017

c)

Price(s) and volume(s):

Sale of shares:

Price(s)

Volume(s)

n/a

n/a

d)

Aggregated information: (Relates to those shares sold only)

Aggregated volume: n/a

Aggregated price: n/a

e)

Date of the transaction: 02/05/2017

f)

Place of the transaction: London Stock Exchange, AIM Market (XLON)

 

 

 

 

 

 

 

1.

a)

Name: Rose Guang

2.

a)

Position/status: Director/PDMR

b)

Initial notification/Amendment: Initial Notification

3.

a)

Name:   Advanced Medical Solutions Group plc

b)

LEI: 213800HJP6OWOSZI1L74

4.

a)

Description of the financial instrument, type of instrument: Ordinary Shares of 5p

Identification code: GB0004536594

b)

Nature of the transactions:

·        Purchase of 7,224 Ordinary Shares as part of the Deferred Share Bonus Plan on 2 May 2017

c)

Price(s) and volume(s):

Sale of shares:

Price(s)

Volume(s)

n/a

n/a

d)

Aggregated information: (Relates to those shares sold only)

Aggregated volume: n/a

Aggregated price: n/a

e)

Date of the transaction: 02/05/2017

f)

Place of the transaction: London Stock Exchange, AIM Market (XLON)

 

 

 

 

 

 

 

1.

a)

Name: Eddie Johnson

2.

a)

Position/status: Director/PDMR

b)

Initial notification/Amendment: Initial Notification

3.

a)

Name:   Advanced Medical Solutions Group plc

b)

LEI: 213800HJP6OWOSZI1L74

4.

a)

Description of the financial instrument, type of instrument: Ordinary Shares of 5p

Identification code: GB0004536594

b)

Nature of the transactions:

·        Purchase of 7,157 Ordinary Shares as part of the Deferred Share Bonus Plan on 2 May 2017

c)

Price(s) and volume(s):

Sale of shares:

Price(s)

Volume(s)

n/a

n/a

d)

Aggregated information: (Relates to those shares sold only)

Aggregated volume: n/a

Aggregated price: n/a

e)

Date of the transaction: 02/05/2017

f)

Place of the transaction: London Stock Exchange, AIM Market (XLON)

 

 

 

 

 

 

 

1.

a)

Name: Becky Walmsley

2.

a)

Position/status: Director/PDMR

b)

Initial notification/Amendment: Initial Notification

3.

a)

Name:   Advanced Medical Solutions Group plc

b)

LEI: 213800HJP6OWOSZI1L74

4.

a)

Description of the financial instrument, type of instrument: Ordinary Shares of 5p

Identification code: GB0004536594

b)

Nature of the transactions:

·        Purchase of 2,381 Ordinary Shares as part of the Deferred Share Bonus Plan on 2 May 2017

c)

Price(s) and volume(s):

Sale of shares:

Price(s)

Volume(s)

n/a

n/a

d)

Aggregated information: (Relates to those shares sold only)

Aggregated volume: n/a

Aggregated price: n/a

e)

Date of the transaction: 02/05/2017

f)

Place of the transaction: London Stock Exchange, AIM Market (XLON)

 

 

 

 

 

 

 

1.

a)

Name: Jeff Willis

2.

a)

Position/status: Director/PDMR

b)

Initial notification/Amendment: Initial Notification

3.

a)

Name:   Advanced Medical Solutions Group plc

b)

LEI: 213800HJP6OWOSZI1L74

4.

a)

Description of the financial instrument, type of instrument: Ordinary Shares of 5p

Identification code: GB0004536594

b)

Nature of the transactions:

·        Purchase of 5,226 Ordinary Shares as part of the Deferred Share Bonus Plan on 2 May 2017

c)

Price(s) and volume(s):

Sale of shares:

Price(s)

Volume(s)

n/a

n/a

d)

Aggregated information: (Relates to those shares sold only)

Aggregated volume: n/a

Aggregated price: n/a

e)

Date of the transaction: 02/05/2017

f)

Place of the transaction: London Stock Exchange, AIM Market (XLON)

 

 

– End –

 

 

 

 

 

 

 

For further information, please visit www.admedsol.com or contact:

 

Advanced Medical Solutions Group plc

Tel: +44 (0) 1606 545508

Chris Meredith, Chief Executive Officer

Mary Tavener, Chief Financial Officer




Consilium Strategic Communications

Tel: +44 (0) 20 3709 5700

Mary-Jane Elliott / Jonathan Birt / Matthew Neal / Hendrik Thys

AMS@consilium-comms.com



Investec Bank PLC (NOMAD & Broker)

Tel: +44 (0) 20 7597 5970

Daniel Adams / Patrick Robb


 

About Advanced Medical Solutions Group plc – see www.admedsol.com

AMS is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical and advanced wound care markets, focused on quality outcomes for patients and value for payors. AMS has a wide range of wound care products that include silver alginates, alginates, foams, tissue adhesives, sutures and haemostats, which it sells under white label as well as its own brand ActivHeal®, and surgical tissue adhesives, sutures and haemostats, which markets under its own brands; LiquiBand® and RESORBA®.

AMS’s products, manufactured out of two sites in the UK, one in the Netherlands, two in Germany and one in the Czech Republic, are sold in more than 70 countries via a network of multinational or regional partners and distributors, as well as via AMS’s own direct sales forces in the UK, Germany, the Czech Republic and Russia.  Established in 1991, the Company has 600 employees.  For more information, please see www.admedsol.com.


This information is provided by RNS
The company news service from the London Stock Exchange
 

END

 
 

DSHBRGDUBGGBGRU

For further information, please contact:

Advanced Medical Solutions Group plc

Tel: 44 (0) 1606 545508

Chris Meredith, Chief Executive Officer

Eddie Johnson, Chief Financial Officer

Michael King, Investor Relations

Consilium Strategic Communications

Tel: 44 (0) 20 3709 5700

Matthew Neal / Lucy Featherstone

Investec Bank PLC (NOMAD & Broker)

Tel: 44 (0) 20 7597 5970

Gary Clarence / David Anderson

HSBC Bank PLC (Broker)

Tel: 44 (0) 20 7991 8888

Sam McLennan / Joe Weaving / Stephanie Cornish

About Advanced Medical Solutions Group plc

AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand®, RESORBA®, LiquiBandFix8® and Seal-G®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. Since 2019, the Group has made five acquisitions: Sealantis, an Israeli developer of innovative internal sealants; Biomatlante, a French developer and manufacturer of surgical biomaterials, Raleigh, a leading UK coater and converter of woundcare and bio-diagnostics materials, AFS Medical, an Austrian specialist surgical business and Connexicon, an Irish tissue adhesives specialist.

AMS's products, manufactured in the UK, Germany, France, the Netherlands, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, Austria, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Ireland, Germany, France and Israel. Established in 1991, the Group has more than 800 employees. For more information, please see admedsol.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.